(Q38774878)

6 September 2017

Metformin; a review of its history and future: from lilac to longevity (English)

1 reference

6 September 2017

1 reference

Inas Thomas

1

1 reference

PubMed ID

28052534

6 September 2017

Brigid Gregg

series ordinal

2

1 reference

6 September 2017

1 February 2017

1 reference

6 September 2017

1 reference

6 September 2017

18

1 reference

6 September 2017

1

1 reference

6 September 2017

10-16

1 reference

Traditional plant medicines as treatments for diabetes

6 September 2017

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12473

Repurposing metformin: an old drug with new tricks in its binding pockets

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12473

A risk-benefit assessment of metformin in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12473

Incidence of lactic acidosis in metformin users

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12473

Oral antihyperglycemic therapy for type 2 diabetes: scientific review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12473

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12473

An update on the pharmacogenomics of metformin: progress, problems and potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12473

Metformin pharmacogenomics: current status and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12473

Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12473

An energetic tale of AMPK-independent effects of metformin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12473

Metabolic effects of metformin in non-insulin-dependent diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12473

Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12473

Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12473

Metformin Increases AMP-Activated Protein Kinase Activity in Skeletal Muscle of Subjects With Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12473

Effect of metformin treatment on insulin action in diabetic rats: in vivo and in vitro correlations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12473

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12473

Metformin: from mechanisms of action to therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12473

Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12473

Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferator-activated receptor-α in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12473

Involvement of glucagon-like peptide-1 in the glucose-lowering effect of metformin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12473

Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12473

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12473

Effects of low dose metformin in adolescents with type I diabetes mellitus: a randomized, double-blinded placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12473

Effect of Metformin Added to Insulin on Glycemic Control Among Overweight/Obese Adolescents With Type 1 Diabetes: A Randomized Clinical Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12473

Effect of Metformin on mortality in patients with heart failure and type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12473

Insulin resistance, role of metformin and other non-insulin therapies in pediatric type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12473

Clinical review: Drugs commonly associated with weight change: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12473

Efficacy and safety of metformin for treatment of overweight and obesity in adolescents: an updated systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12473

10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12473

Metformin: prevention and treatment of antipsychotic-induced weight gain

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12473

Adjunctive metformin for antipsychotic-induced hyperprolactinemia: A systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12473

Effects of Metformin and Exercise Training, Alone or in Combination, on Cardiac Function in Individuals with Insulin Resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12473

Lipid and inflammatory cardiovascular risk worsens over 3 years in youth with type 2 diabetes: the TODAY clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12473

Evaluating the Effects of Metformin Use on Height in Children and Adolescents: A Meta-analysis of Randomized Clinical Trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12473

Metformin treatment to reduce central adiposity after prenatal growth restraint: a placebo-controlled pilot study in prepubertal children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12473

Metformin treatment for four years to reduce total and visceral fat in low birth weight girls with precocious pubarche.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12473

Metformin Treatment to Prevent Early Puberty in Girls with Precocious Pubarche

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12473

Pubertal metformin therapy to reduce total, visceral, and hepatic adiposity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12473

Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12473

Synergistic Benefit of Statin and Metformin in Gastrointestinal Malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12473

Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12473

Metformin--mode of action and clinical implications for diabetes and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12473

Short- and long-term outcomes of metformin compared with insulin alone in pregnancy: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12473

Metformin elicits anticancer effects through the sequential modulation of DICER and c-MYC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12473

Metformin in gestational diabetes: the offspring follow-up (MiG TOFU): body composition at 2 years of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12473

Activating Endogenous Neural Precursor Cells Using Metformin Leads to Neural Repair and Functional Recovery in a Model of Childhood Brain Injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12473

Treatment with L-citrulline and metformin in Duchenne muscular dystrophy: study protocol for a single-centre, randomised, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12473

Metformin use and lung cancer risk in patients with diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12473

Once-daily delayed-release metformin lowers plasma glucose and enhances fasting and postprandial GLP-1 and PYY: results from two randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12473

Reasons and outcomes of conversion of laparoscopic sleeve gastrectomy to Roux-en-Y gastric bypass for nonresponders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12473

Therapeutic Challenges in Diabetes Prevention: We Have Not Found the "Exercise Pill"

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12473

Potential biomarker of metformin action

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12473

21 January 2018

Identifiers

DOI

10.1111/PEDI.12473

1 reference

6 September 2017

1 reference

PubMed ID

28052534